Published in PLoS One on November 14, 2012
Repair of astrocytes, blood vessels, and myelin in the injured brain: possible roles of blood monocytes. Mol Brain (2013) 0.88
The neurotrophic hepatocyte growth factor attenuates CD8+ cytotoxic T-lymphocyte activity. J Neuroinflammation (2013) 0.81
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Immunology of multiple sclerosis. Annu Rev Immunol (2005) 9.08
Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity (2008) 3.67
Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature (1992) 3.39
Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology (2002) 2.34
Hepatocyte growth factor mediates mesenchymal stem cell–induced recovery in multiple sclerosis models. Nat Neurosci (2012) 1.86
Hepatocyte growth factor/scatter factor is an axonal chemoattractant and a neurotrophic factor for spinal motor neurons. Neuron (1996) 1.73
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood (2006) 1.60
Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions. Exp Neurol (2006) 1.55
A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. J Immunol (2005) 1.49
Brain-derived neurotrophic factor rescues developing avian motoneurons from cell death. Nature (1993) 1.33
Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci U S A (2009) 1.31
Hepatocyte growth factor, a versatile signal for developing neurons. Nat Neurosci (1999) 1.24
Expression and functional interaction of hepatocyte growth factor-scatter factor and its receptor c-met in mammalian brain. J Cell Biol (1994) 1.21
Selective depletion of CD14+ CD16+ monocytes by glucocorticoid therapy. Clin Exp Immunol (1998) 1.17
Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A (2010) 1.16
Neurotrophic effect of hepatocyte growth factor on central nervous system neurons in vitro. J Neurosci Res (1996) 1.12
Localization and functional coupling of HGF and c-Met/HGF receptor in rat brain: implication as neurotrophic factor. Brain Res Mol Brain Res (1995) 1.10
Hepatocyte growth factor promotes endogenous repair and functional recovery after spinal cord injury. J Neurosci Res (2007) 1.08
Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study. Am J Pathol (2006) 1.06
Hepatocyte growth factor is a regulator of monocyte-macrophage function. J Immunol (2001) 1.05
TGF-beta-treated microglia induce oligodendrocyte precursor cell chemotaxis through the HGF-c-Met pathway. Eur J Immunol (2005) 1.05
Hepatocyte growth factor stimulates the proliferation and migration of oligodendrocyte precursor cells. J Neurosci Res (2002) 1.04
Hepatocyte growth factor (HGF) promotes oligodendrocyte progenitor cell proliferation and inhibits its differentiation during postnatal development in the rat. Brain Res (2007) 0.96
Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann Neurol (2007) 0.94
The role of hepatocyte growth factor and its receptor c-met in interactions between lymphocytes and stromal cells in secondary human lymphoid organs. Immunology (2001) 0.93
New pieces in the puzzle: how does interferon-beta really work in multiple sclerosis? Ann Neurol (2009) 0.92
Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch Neurol (2005) 0.91
Selective expression of the Met/HGF receptor in human central nervous system microglia. Oncogene (1993) 0.89
Human hepatocyte growth factor promotes functional recovery in primates after spinal cord injury. PLoS One (2011) 0.88
Hepatocyte growth factor in cerebrospinal fluid in neurologic disease. Acta Neurol Scand (2002) 0.87
Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin. Pharm Res (1993) 0.87
Hepatocyte growth factor (HGF) attenuates gliosis and motoneuronal degeneration in the brainstem motor nuclei of a transgenic mouse model of ALS. Neurosci Res (2007) 0.87
Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology (1996) 0.86
Cerebrospinal hepatocyte growth factor levels correlate negatively with disease activity in multiple sclerosis. J Neuroimmunol (2012) 0.83
Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients. J Neuroimmunol (2008) 0.82
Hepatocyte growth factor specifically expressed in microglia activated Ras in the neurons, similar to the action of neurotrophic factors. Biochem Biophys Res Commun (1995) 0.80
MHC class II-restricted antigen presentation by plasmacytoid dendritic cells inhibits T cell-mediated autoimmunity. J Exp Med (2010) 2.00
Opsoclonus-myoclonus syndrome in anti-N-methyl-D-aspartate receptor encephalitis. Arch Neurol (2010) 1.52
Developing priorities for addressing surgical conditions globally: furthering the link between surgery and public health policy. World J Surg (2010) 1.34
Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci U S A (2009) 1.31
Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A (2010) 1.16
Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs (2011) 1.15
Strengthening care of injured children globally. Bull World Health Organ (2009) 1.02
Neurofilament ELISA validation. J Immunol Methods (2009) 0.96
Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease. PLoS One (2010) 0.93
Glatiramer acetate triggers PI3Kδ/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes. Proc Natl Acad Sci U S A (2010) 0.93
Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J Allergy Clin Immunol (2005) 0.92
Antibody response in MOG(35-55) induced EAE. J Neuroimmunol (2011) 0.90
Apoptotic effects of Human Herpesvirus-6A on glia and neurons as potential triggers for central nervous system autoimmunity. J Clin Virol (2006) 0.89
Relevant antibody subsets against MOG recognize conformational epitopes exclusively exposed in solid-phase ELISA. Eur J Immunol (2007) 0.89
IgG glycan hydrolysis by EndoS inhibits experimental autoimmune encephalomyelitis. J Neuroinflammation (2012) 0.89
Hospital-based injury data from level III institution in Cameroon: retrospective analysis of the present registration system. Injury (2011) 0.87
Dual-task assessment in natalizumab-treated multiple sclerosis patients. Eur Neurol (2014) 0.86
Conformational epitopes of myelin oligodendrocyte glycoprotein are targets of potentially pathogenic antibody responses in multiple sclerosis. J Neuroinflammation (2011) 0.85
Exploring the human tear fluid: discovery of new biomarkers in multiple sclerosis. Proteomics Clin Appl (2014) 0.84
Selective APRIL blockade delays systemic lupus erythematosus in mouse. PLoS One (2012) 0.84
Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model. Int Immunol (2008) 0.81
Encephalitis associated with glutamic acid decarboxylase autoantibodies in a child: a treatable condition? Arch Neurol (2011) 0.81
Fingolimod in a patient with Wolff-Parkinson-White syndrome. Mult Scler (2013) 0.81
The neurotrophic hepatocyte growth factor attenuates CD8+ cytotoxic T-lymphocyte activity. J Neuroinflammation (2013) 0.81
Infection following deep brain stimulator implantation performed in the conventional versus magnetic resonance imaging-equipped operating room. J Neurosurg (2009) 0.81
Increasing the diagnostic value of evoked potentials in multiple sclerosis by quantitative topographic analysis of multichannel recordings. J Clin Neurophysiol (2009) 0.79
TLR7 signaling exacerbates CNS autoimmunity through downregulation of Foxp3+ Treg cells. Eur J Immunol (2013) 0.78
VGKC antibody-associated encephalitis, microbleeds and progressive brain atrophy. J Neurol (2009) 0.78
Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases. PLoS One (2013) 0.77
Cerebrospinal fluid anti-SSA autoantibodies in primary Sjogren's syndrome with central nervous system involvement. Eur Neurol (2007) 0.76
Nogo-A downregulation improves insulin secretion in mice. Diabetes (2012) 0.75
Mild clinical expression of Lambert-Eaton myasthenic syndrome in a patient with HIV infection. BMJ Case Rep (2009) 0.75
Mild clinical expression of Lambert-Eaton myasthenic syndrome in a patient with HIV infection. J Neurol Neurosurg Psychiatry (2007) 0.75
Magnetic resonance imaging in multiple sclerosis. Top Magn Reson Imaging (2009) 0.75
[Clinical pharmacology of medical cannabinoids in chronic pain]. Rev Med Suisse (2015) 0.75
[In Process Citation]. Rev Med Suisse (2016) 0.75
[Myasthenia gravis: treatments and remissions]. Rev Med Suisse (2007) 0.75
[Paraneoplastic neurological syndromes: an update]. Rev Med Suisse (2016) 0.75
[The painful multiple sclerosis]. Rev Med Suisse (2008) 0.75
Multifocal motor neuropathy with high titers of anti-MAG antibodies. J Peripher Nerv Syst (2014) 0.75